Published in Retrovirology on October 16, 2013
Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLoS Pathog (2016) 1.50
Multiple Origins of Virus Persistence during Natural Control of HIV Infection. Cell (2016) 1.23
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. J Virol (2013) 0.89
SAMHD1 expression in blood cells of HIV-1 elite suppressors and viraemic progressors. J Antimicrob Chemother (2014) 0.86
Dynamic regulation of host restriction factor expression over the course of HIV-1 infection in vivo. J Virol (2014) 0.85
HIV-1 functional cure: will the dream come true? BMC Med (2015) 0.84
A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers. Cell Host Microbe (2014) 0.83
Antiviral gene expression in psoriasis. J Eur Acad Dermatol Venereol (2015) 0.82
Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS (2015) 0.81
Role of microRNA modulation in the interferon-α/ribavirin suppression of HIV-1 in vivo. PLoS One (2014) 0.80
IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection. Nat Commun (2015) 0.79
SAMHD1 transcript upregulation during SIV infection of the central nervous system does not associate with reduced viral load. Sci Rep (2016) 0.78
IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI Insight (2017) 0.77
miRNAs and SAMHD1 regulation in vitro and in a model of HIV CNS disease. J Neuroinflammation (2015) 0.76
Escherichia coli surface display of single-chain antibody VRC01 against HIV-1 infection. Virology (2014) 0.76
COMMD1/Murr1 reinforces HIV-1 latent infection through IκB-α stabilization. J Virol (2014) 0.76
Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo. J AIDS Clin Res (2015) 0.75
HIV Replication Is Not Controlled by CD8+ T Cells during the Acute Phase of the Infection in Humanized Mice. PLoS One (2015) 0.75
Evolutionary distance of amino acid sequence orthologs across macaque subspecies: identifying candidate genes for SIV resistance in Chinese rhesus macaques. PLoS One (2015) 0.75
Relative mRNA Expression Levels of Restriction Factors and Antiviral Genes in Fetal and Adult Human Monocytes and Monocyte-Derived Macrophages. Viral Immunol (2017) 0.75
Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment. Oncotarget (2016) 0.75
BCL6 represses antiviral resistance in follicular T helper cells. J Leukoc Biol (2017) 0.75
Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol (2017) 0.75
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe (2008) 9.27
Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature (2011) 7.92
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science (1987) 5.22
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature (2007) 4.13
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem (2004) 3.56
Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci U S A (1987) 3.47
Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature (2012) 2.98
Antiretroviral therapy and management of HIV infection. Lancet (2010) 2.84
The IFITM proteins inhibit HIV-1 infection. J Virol (2010) 2.80
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A (2002) 2.32
The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog (2008) 2.06
TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog (2008) 2.05
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog (2011) 1.90
Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog (2010) 1.90
Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest (2007) 1.88
Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med (2008) 1.85
Human TRIM gene expression in response to interferons. PLoS One (2009) 1.84
Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol (2007) 1.74
CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest (2011) 1.71
Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem (2008) 1.68
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A (2012) 1.65
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood (2011) 1.62
Perturbation of the P-body component Mov10 inhibits HIV-1 infectivity. PLoS One (2010) 1.51
Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis (2010) 1.50
Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol (2007) 1.47
The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. J Virol (2010) 1.42
A whole genome screen for HIV restriction factors. Retrovirology (2011) 1.37
Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog (2007) 1.22
HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood (2012) 1.21
Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers. J Virol (2010) 1.12
Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology (2008) 1.10
Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol (2010) 1.10
Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. J Leukoc Biol (2013) 1.09
Silencing p21(Waf1/Cip1/Sdi1) expression increases gene transduction efficiency in primitive human hematopoietic cells. Gene Ther (2005) 1.08
CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors. Proc Natl Acad Sci U S A (2011) 1.05
Human HERC5 restricts an early stage of HIV-1 assembly by a mechanism correlating with the ISGylation of Gag. Retrovirology (2011) 1.05
Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells. J Virol (2013) 1.05
Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease. Front Immunol (2013) 0.91
How do HIV elite controllers do what they do? Clin Infect Dis (2010) 0.91
Identification of molecular determinants from Moloney leukemia virus 10 homolog (MOV10) protein for virion packaging and anti-HIV-1 activity. J Biol Chem (2011) 0.89
Mutations in the nef and vif genes associated with progression to AIDS in elite controller and slow-progressor patients. J Med Virol (2013) 0.84
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis (2003) 8.00
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 5.94
Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 5.76
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 4.87
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell (2005) 4.30
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr (2010) 4.20
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91
Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 3.73
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS (2006) 3.70
Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol (2004) 3.58
Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol (2002) 3.57
Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature (2010) 3.57
Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A (2011) 3.53
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother (2004) 3.48
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood (2010) 3.32
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol (2007) 3.31
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One (2008) 3.13
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS (2009) 3.08
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS (2006) 2.98
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis (2010) 2.98
Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature (2012) 2.98
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med (2008) 2.94
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Antiretroviral therapy and management of HIV infection. Lancet (2010) 2.84
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. J Immunol Methods (2009) 2.78
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation (2010) 2.71
Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep (2007) 2.68
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS (2012) 2.65
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis (2011) 2.56
History-adjusted marginal structural models for estimating time-varying effect modification. Am J Epidemiol (2007) 2.56
Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med (2013) 2.47
Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis (2012) 2.45
HIV: Shock and kill. Nature (2012) 2.45
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (2011) 2.43
Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood (2009) 2.43